Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 8/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13051900 | 0.88 | ICMT (0.36) | ICMTGRIN1GRIN2BSRCKCNH2 | |
| SCHEMBL2884324 | 0.86 | KCNH2 (0.39) | ICMTGRIN1GRIN2BSRCKCNH2 | |
| SCHEMBL2884731 | 0.84 | SIGMAR1 (0.43) | ICMTGRIN1GRIN2BSRCKCNH2 | |
| SCHEMBL2886366 | 0.80 | TP53 (0.42) | ICMTMAPTCNR2TP53 | |
| SCHEMBL12995603 | 0.79 | ALDH1A1 (0.42) | LMNAMAPTCNR2TP53 | |
| SCHEMBL12995832 | 0.78 | TP53 (0.41) | ICMTSRCKCNH2MAPTCNR2 | |
| SCHEMBL13051902 | 0.78 | SRC (0.41) | ICMTGRIN1GRIN2BSRCKCNH2 | |
| SCHEMBL13051899 | 0.74 | KCNH2 (0.42) | ICMTGRIN1GRIN2BSRCKCNH2 | |
| SCHEMBL2883878 | 0.74 | KCNH2 (0.39) | ICMTGRIN1GRIN2BSRCKCNH2 | |
| SCHEMBL2883977 | 0.72 | SIGMAR1 (0.43) | ICMTGRIN1GRIN2BSRCKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ICMT 2203/4885GRIN1 2906/4885GRIN2B 3542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.